YOLFTbeta
IB

Infant Bacterial Therapeutics AB (publ)

IBT-B · ST · Healthcare / Biotechnology

66.00SEK-7.30 (-9.96%)

Price History

Full chart

Market Stats

Previous Close73.30
Open68.00
Day Range60.70 – 70.00
52-Week Range43.25 – 76.10
Volume35.87K
Market Cap936.26M
P/E (TTM)0.00
Forward P/E0.00
EPS-6.08
Dividend Yield0.00%
Beta0.35
50-Day Avg65.96
200-Day Avg57.49

About

Infant Bacterial Therapeutics AB (publ) operates as a clinical stage pharmaceutical company develops and markets drugs to prevent serious neonatal diseases affecting premature infants in Sweden. The company's lead drug candidate is IBP-9414, which has completed Phase III clinical studies to prevent necrotizing enterocolitis, as well as to improve feeding tolerance in premature infants. It is also developing IBP-1016 for the treatment of gastroschisis, a rare and severe birth abnormality in infants. In addition, its drug candidates include IBP-1118 to prevent retinopathy of prematurity that causes blindness in premature babies; and IBP-1122, indicated to eliminate vancomycin resistant enterococci that cause antibiotic resistant hospital infections. The company was incorporated in 2011 and is headquartered in Stockholm, Sweden.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Staffan Stromberg Ph.D.
  • Employees6
  • HeadquartersKatarina Bangata 70, Stockholm, Sweden, 116 42, Sweden
  • Websitehttps://www.ibtherapeutics.com

Leadership

  • Mr. Staffan Stromberg Ph.D.Chief Executive Officer · b. 1967
  • Ms. Maria EkdahlChief Financial Officer · b. 1973
  • Mr. Anders Kronstrom M.B.A., M.S.Chief Operating Officer · b. 1967
  • Dr. Thomas J. Schnitzer M.D., Ph.D.Chief Scientific Officer
  • Mr. Sanjiv Sharma M.B.A.Head of Medical Affairs · b. 1956

Financials

Income Statement

Currency: SEK2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue----162.00K238.00K000012.00K77.00K4.00K0
Growth (%)-----+46.91%-100.00%----+541.67%-94.81%-100.00%
Cost of Revenue----811.00K-816.00K816.00K------
Gross Profit-----649.00K238.00K-816.00K-816.00K--12.00K77.00K4.00K-
Gross Margin-----400.62%100.00%----100.00%100.00%100.00%-
Operating Expense----37.44M36.38M38.60M46.38M--65.82M134.69M139.91M-
Operating Income-1.71K-228.83K-6.59M-20.61M-38.09M-36.14M-39.42M-47.20M-71.92M-44.58M-65.81M-134.62M-139.90M-61.95M
Operating Margin-----23512.35%-15185.29%-----548400.00%-174827.27%-3497550.00%-
EBITDA-1.71K228.83K-17.04K-20.61M-37.30M-35.33M-39.79M-45.50M-70.89M-43.76M-64.34M11.55M-136.91M-68.18M
EBITDA Margin-----23021.60%-14842.44%-----536183.33%14998.70%-3422625.00%-
Net Income-1.71K--6.75M-20.62M-38.11M-36.16M-40.61M-47.05M-72.31M-44.99M-65.45M-123.07M-136.91M-65.17M
Net Income Margin-----23522.22%-15191.60%-----545425.00%-159828.57%-3422625.00%-
R&D-228.83K6.59M17.97M40.80M36.38M39.42M47.20M72.23M44.67M65.82M121.18M120.61M48.85M
R&D as % of Total Revenue----25182.10%15285.29%----548500.00%157380.52%3015150.00%-
Interest Expense--156.00K9.00K16.00K15.00K1.52M725.00K303.00K413.00K293.00K9.00K00
Interest Expense % of Total Revenue----9.88%6.30%----2441.67%11.69%0.00%-

Balance Sheet

Currency: SEK2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets48.15K1.29M14.54M82.54M110.11M175.02M563.37M518.27M450.32M408.48M349.62M351.33M239.57M161.75M
Total Liabilities-240.70K3.51M7.73M4.88M6.65M6.65M7.88M10.16M13.22M17.91M46.18M69.30M56.42M
Total Equity48.15K1.05M11.03M74.81M105.23M168.37M556.72M510.40M440.15M395.25M331.71M305.15M170.26M105.33M
Cash48.15K901.30K1.05M44.41M93.79M158.27M542.17M495.19M423.44M386.75M335.84M329.06M223.39M144.01M
Net Debt-48.15K-901.30K-1.05M-44.41M-93.79M-158.27M-542.17M-495.19M-423.44M-386.75M-335.84M-329.06M-223.39M-144.01M

Cash Flow

Currency: SEK2012-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow--3.77M-17.02M-39.75M-34.76M-47.41M-51.30M-58.39M-55.62M-85.80M-101.22M-113.13M-72.34M
Investing Cash Flow--6.08M-10.15M-50.00K-50.00K0----1.00K-4.15M--
Financing Cash Flow-10.00M70.53M89.12M99.30M428.95M1.76M1.76M91.00K1.88M96.52M2.01M0
Capital Expenditure0010.15M050.00K00000000
Free Cash Flow--3.77M-27.17M-39.75M-34.81M-47.41M-51.30M-58.39M-55.62M-85.80M-101.22M-113.13M-72.34M
FCF to OCF-100.00%159.62%100.00%100.14%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%

Earnings

Report DateMar 31, 2017Jun 30, 2017Sep 30, 2017Feb 28, 2018May 15, 2018Aug 16, 2018Nov 14, 2018Feb 8, 2019May 6, 2019Aug 21, 2019Nov 7, 2019Feb 11, 2020May 11, 2020Aug 14, 2020Nov 5, 2020Feb 5, 2021May 4, 2021Aug 13, 2021Oct 29, 2021Feb 4, 2022May 4, 2022Aug 25, 2022Nov 10, 2022Feb 10, 2023May 8, 2023Aug 25, 2023Nov 10, 2023Feb 8, 2024May 7, 2024Aug 28, 2024Nov 14, 2024Feb 13, 2025May 7, 2025Aug 20, 2025Nov 13, 2025Feb 6, 2026May 5, 2026Aug 26, 2026
EPS Estimate---------2.27-2.39-2.32-2.48--------------------------
EPS Actual-1.39-2.25-0.75-1.38-0.960.06-0.71-2.15-0.06-0.67-0.94-2.450.10-2.49-1.66-2.380.04-2.60-0.01-1.44-1.710.15-0.69-3.57-2.00-2.57-2.31-3.04-2.06-3.17-2.42-2.51-1.24-1.42-0.75-1.43-1.70-2.21
Surprise--------97.36%71.97%59.48%1.21%--------------------------
Timing---Pre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-market---------Pre-marketAfter-hoursPre-marketAfter-hoursPre-marketAfter-hoursPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market-

Key Statistics & Ratios

Market Cap936.26M
Enterprise Value800.72M
Trailing P/E0.00
Forward P/E0.00
Price / Sales10837.29
Price / Book17.15
EPS-6.08
Book Value3.94
Revenue (TTM)-1.00K
Gross Profit (TTM)-1.00K
EBITDA-133.80M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-87.44%
Return on Assets-33.89%
Shares Outstanding13.02M
Shares Float11.23M
Beta0.35
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%